Alpha Tau Medical Ltd. (DRTSW) — SEC Filings
Alpha Tau Medical Ltd. (DRTSW) — 43 SEC filings. Latest: 6-K (Dec 18, 2025). Includes 42 6-K, 1 20-F.
View Alpha Tau Medical Ltd. on SEC EDGAR
Overview
Alpha Tau Medical Ltd. (DRTSW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 18, 2025: Alpha Tau Medical Ltd. announced on December 18, 2025, that it will present at the J.P. Morgan 2026 Healthcare Conference. The company, headquartered in Jerusalem, Israel, is involved in surgical and medical instruments and apparatus.
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 9 bullish, 34 neutral. The dominant filing sentiment for Alpha Tau Medical Ltd. is neutral.
Filing Type Overview
Alpha Tau Medical Ltd. (DRTSW) has filed 42 6-K, 1 20-F with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of DRTSW's 41 recent filings, 0 were flagged as high-risk, 15 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Alan Adler
- S. Morry Blumenfeld
- Nadav Kidron
- Michael Avruch
- Uzi Sofer
- Maya Netser
Top Tags
medical-technology (7) · investor-relations (7) · conference-participation (7) · conference-presentation (5) · oncology (5) · press-release (5) · medical-devices (5) · clinical-trial (4) · corporate-governance (4) · financial-results (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Investor Conferences | 5 | Number of conferences Alpha Tau Medical will attend in September 2025. |
| Gross Proceeds | $28.2M | Raised from the registered direct offering. |
| Shares Sold | 14,110,121 | Number of ordinary shares sold in the offering. |
| Price Per Share | $2 | Purchase price for each ordinary share. |
| Fiscal Year End | 2024 | The period covered by the annual report. |
| SEC File Number | 001-41316 | Unique identifier for the company's filings. |
| Patients | 30 | Number of patients to be included in the expanded pilot trial for pancreatic cancer. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Alpha Tau Medical Ltd. (DRTSW)?
Alpha Tau Medical Ltd. has 43 recent SEC filings from Feb 2024 to Dec 2025, including 42 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DRTSW filings?
Across 43 filings, the sentiment breakdown is: 9 bullish, 34 neutral. The dominant sentiment is neutral.
Where can I find Alpha Tau Medical Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Alpha Tau Medical Ltd. (DRTSW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Alpha Tau Medical Ltd.?
Financial highlights for Alpha Tau Medical Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for DRTSW?
Investment thesis data for DRTSW will be available once enriched filings are processed.
Who are the key executives at Alpha Tau Medical Ltd.?
Key executives identified across Alpha Tau Medical Ltd.'s filings include Alan Adler, S. Morry Blumenfeld, Nadav Kidron, Michael Avruch, Uzi Sofer and 1 others.
What are the main risk factors for Alpha Tau Medical Ltd. stock?
Of DRTSW's 41 assessed filings, 0 were flagged high-risk, 15 medium-risk, and 26 low-risk.
What are recent predictions and forward guidance from Alpha Tau Medical Ltd.?
Forward guidance and predictions for Alpha Tau Medical Ltd. are extracted from SEC filings as they are enriched.